About Alzinova
Alzinova AB is a Swedish pharmaceutical enterprise engaged in drug discovery research for Alzheimer’s disease. The company's proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.
Read more »Research
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the synapse-damaging oligomers.
Press Releases
-
2020-05-14
Communiqué from the Annual General Meeting of Alzinova AB (publ) on 14 May 2020
-
2020-05-14
Kommuniké från Alzinova AB (publ) årsstämma den 14 maj 2020
-
2020-04-15
NOTICE OF ANNUAL GENERAL MEETING IN Alzinova AB (publ)
-
2020-04-15
KALLELSE TILL ÅRSSTÄMMA i Alzinova AB (publ)
-
2020-03-05
Alzinova appoints new Chief Financial Officer
-
2020-03-05
Alzinova tillsätter ny Chief Financial Officer